Ferroptosis and Autoimmune Diseases

Benjamin Lai¹, Chien-Hsiang Wu², Chao-Yi Wu³⁴, Shue-Fen Luo² and Jenn-Haung Lai²⁵*

¹ Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ² Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ³ Division of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁴ College of Medicine, Chang Gung University, Taoyuan, Taiwan, ⁵ Graduate Institute of Medical Science, National Defense Medical Center, Taipei, Taiwan

Adequate control of autoimmune diseases with an unclear etiology resulting from autoreactivation of the immune system remains a major challenge. One of the factors that trigger autoimmunity is the abnormal induction of cell death and the inadequate clearance of dead cells that leads to the exposure or release of intracellular contents that activate the immune system. Different from other cell death subtypes, such as apoptosis, necroptosis, autophagy, and pyroptosis, ferroptosis has a unique association with the cellular iron load (but not the loads of other metals) and preserves its distinguishable morphological, biological, and genetic features. This review addresses how ferroptosis is initiated and how it contributes to the pathogenesis of autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and inflammatory bowel diseases. The mechanisms responsible for ferroptosis-associated events are discussed. We also cover the perspective of targeting ferroptosis as a potential therapeutic for patients with autoimmune diseases. Collectively, this review provides up-to-date knowledge regarding how ferroptosis occurs and its significance in autoimmune diseases.

Keywords: ferroptosis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel diseases, inflammation

INTRODUCTION

Autoimmune diseases are a group of complicated diseases with unknown etiologies. Different autoimmune diseases may share certain similarities in their clinical presentations and yet preserve unique characteristics in each individual autoimmune disease. For example, patients with rheumatoid arthritis (RA) suffer mainly from polyarthritis involving the hand joints, and the extra-articular major organ like kidney is less commonly involved. Different from RA, patients with systemic lupus erythematosus (SLE) may have multiple organ involvement due to overproduction of a variety of autoantibodies and the deposition of antibody-antigen immune complexes in various organs, such as the kidney, causing organ damage. In comparison, although oligoarthritis can occur in certain populations of patients with inflammatory bowel disease (IBD), the major presentation of IBD is chronic intestinal inflammation. Extensive studies have been conducted to identify the factors causing immune activation in autoimmune diseases. One of these directions has focused on investigating the occurrence of abnormal or increased cell death and the inadequate clearance of...
dead cells that leads to the release of the intracellular contents from the dead cells to trigger inflammatory reactions.

While screening for antitumor compounds, the group led by Stockwell BR synthesized and identified two major compound types displaying synthetic lethality with oncogenic RAS in cancer cell lines. One of these compounds is erastin, and the other is RAS synthetic lethal 3 (RSL3) and RSL5, which facilitate iron-dependent, nonapoptotic cell death in cancer cells expressing an oncogenic isofrom of RAS (1, 2). The authors observed that cells transformed with oncogenic RAS have an increased iron load compared with their untransformed counterparts by upregulating transferrin receptor 1 and downregulating ferritin heavy chain 1 and ferritin light chain (2). Erastin and RSLs do not target RAS but rather bind to voltage-dependent anion channels to induce RAS-RAF-MEK-dependent oxidation and nonapoptotic cell death (3). These studies raised an interesting observation that links nonapoptotic cell death with cellular iron load.

Ferroptosis was first proposed by Dixon et al. based on the observation that cell death induced by erastin or RSL showed an increase in cytosolic, and lipid reactive oxygen species (ROS) and cell death can be suppressed by cotreatment with the iron chelator deferoxamine (4). Coincubation with different exogenous sources of iron, but not other divalent metal ions, such as Cu²⁺, Mn²⁺, Ni²⁺, and Co²⁺, potentiated erastin-induced cell death (4). Several features of ferroptosis, including loss of membrane integrity, increased membrane density, shrinking mitochondria and rupture of the outer mitochondrial membrane with morphologically normal nuclei distinguish this death subtype from other cell death subtypes, such as apoptosis, necrosis and autophagy (4–7). Phenotypically, ferroptosis shares a certain similarity with H₂O₂-induced necrosis; however, the ATP pool that is depleted in H₂O₂-induced necrosis is not affected in ferroptosis (4). Different organelles, such as lysosomes and the endoplasmic reticulum (ER), are involved in the processes of ferroptosis (8). The authors analyzed a shRNA library targeting mainly mitochondrial genes and observed that erastin-induced ferroptosis was regulated by a subset of genes, such as ribosomal protein L8, iron responsive element binding protein 2, ATP5G3, TPR repeat protein 35, citrate synthase and acyl-CoA synthetase family member 2, which are different from those involved in staurosporine-induced apoptosis (4). The studies thus provide strong evidence that an iron-dependent accumulation of ROS contributes to ferroptosis. Following these early studies, subsequent works revealed that ferroptosis occurs in many clinical disorders, such as kidney disease, cardiomyopathy, atherosclerosis, neurodegenerative disorders, ischemia/reperfusion (I/R) injury, cancers and immune-mediated diseases, such as diabetes, multiple sclerosis, and asthma (9, 10). In comparison, given that most of the published studies have focused on investigating the roles of ferroptosis in cancer (11), knowledge about the involvement and mechanisms of ferroptosis in autoimmune diseases remains largely unclear.

To discuss how ferroptosis is involved in the pathogenesis of autoimmune diseases, some prototypic autoimmune diseases were chosen based upon the accessible messages from published work. Accordingly, several autoimmune disorders, such as SLE, RA, and IBD, were chosen as examples for a discussion of ferroptosis. Importantly, several interesting studies recently reported that ferroptosis contributes to the pathogenesis of these three distinctive autoimmune diseases that do share some similarities. In addition to ferroptosis, other subtypes of cell death such as apoptosis, necroptosis and pyroptosis can also be detected in immune or non-immune cells in patients with SLE, RA and IBD (12–18). Furthermore, in addition to that in SLE, RA and IBD, ferroptosis also play roles in the pathogenesis of multiple sclerosis, an autoimmune neurological disorder, with mechanisms involving the reduced expression of Gpx4 mRNA in the gray matter of multiple sclerosis patients and decreased Gpx4 protein levels in experimental autoimmune encephalomyelitis mice (19). This review specifically addresses how ferroptosis occurs and the factors that trigger ferroptosis as well as the underlying mechanisms in patients with SLE, RA and IBD. Furthermore, we will discuss the perspective of targeting ferroptosis to achieve better therapeutic control of autoimmune diseases.

### Distinguishing Features of Different Cell Death Subtypes

Apoptosis is a noninflammatory form of programmed cell death mediated by the activation of caspases that occurs in a well-organized manner (Table 1). Apoptosis is generally considered a mechanism that occurs under physiological conditions (20, 21). Apoptosis can be executed by sensing intrinsic signals such as cell stress or by sensing extrinsic signals delivered from outside cells as the commonly recognized extrinsic pathway and extrinsic pathway, respectively. Activation of the intrinsic pathway depends on the release of mitochondrial proteins from the mitochondria, whereas activation of the extrinsic pathway is mediated by extracellular ligands that bind to death receptors on the cell surface; caspases, such as caspases 3, 8, and 9, are involved in apoptotic pathways (22). In addition to caspases, B-cell lymphoma-2 (Bcl-2) family members, death receptors, and members of the tumor necrosis factor (TNF) receptor superfamily are individually involved in the intrinsic and extrinsic apoptotic pathways (23). Aside from the changes in mitochondria (24), the characteristic features of apoptosis are membrane blebbing, chromatin condensation and margination, and exposure of membrane phosphatidylserine that induces phagocytosis of apoptotic cells by macrophages (25, 26). Importantly, the intact plasma membrane during apoptosis prevents the release of intracellular content, a process that can potentially trigger overwhelming immune responses. In comparison, a unique feature of necroptosis is swelling of the cytoplasmic organelles, dilated perinuclear space and permeabilization and rupture of the plasma membrane, suggesting the morphological features of necrosis (27–29). In addition, under electron microscopic examination, the electron density of the nucleus is maintained in the early phase and then the nucleus progresses to show sickle-like morphology in the late phase due to compression of the inner nuclear membrane by the
unsuccessful caspase-mediated cleavage of RIPK1 may lead to inflammatory responses and cause tissue injury (41). Given that the different subtypes of cell death preserve their individual unique features and the underlying mechanisms and involved molecules vary, crosstalk or linkages among the different cell death pathways exist. One example is that RIPK1 and caspase-8 regulate the crosstalk between apoptosis, necroptosis, and pyroptosis (42). The interaction between autophagy and apoptosis involving a complex array of biomarkers to coordinate and regulate cell survival or death was also recently addressed in cancers (43).

In addition to the distinguishable morphological changes in ferroptotic cells, one unique feature of ferroptosis is that it does not involve death receptors or sensors to trigger the ferroptotic processes (21). The signaling pathways involved in apoptosis and other cell death subtypes, including cytochrome c release, caspase activation, and activation of receptor-interacting protein 1 and MLKL, do not necessarily participate in ferroptosis, necroptosis, and pyroptosis (42).

**Table 1: Distinguished features of different subtypes of cell death**

| Membrane features | Nuclear characteristics | Organelle morphology | Biochemical determinants |
|-------------------|-------------------------|----------------------|-------------------------|
| Membrane blebbing; exposure of membrane phosphatidylserine | Nuclear shrink, nuclear fragmentation, chromatin condensation and margination | Swollen mitochondria, mitochondrial outer membrane permeabilization | Caspases (2, 3, 6-10), Bcl-2 family members, death receptors, TNF receptor superfamily members |
| Membrane permeabilization and disruption | Maintaining nuclear electron density in early phase and becoming sickle-like morphology of nucleus due to compression of the inner nuclear membrane by the dilated perinuclear space (under EM) | Cytoplasmic swelling, opening of the mitochondrial permeability transition pores | RIPK1, RIPK3, MLKL, IKKe, TBK1 |
| Formation of membrane pores and membrane rupture | Peculiar form of chromatin condensation and intact nuclei | Intact and swollen mitochondria with reduced matrix density and collapsed cristae (under EM) | Caspases (1/4/5 in human; 11 in mice), IL-1β, IL-18, GSDMD |
| Rupture of plasma membrane (due to accumulation of high lipid peroxides) | No nuclear morphological changes but with lucent nucleus under EM and yet with oxidative damage of nuclear DNA | Swollen mitochondria, increase in mitochondrial membrane density, disappearance of mitochondrial cristae | Iron load, Gpx4, ACSL4, POR, CYB5R1, lipid peroxidation |

* There are interactions or overlapping features among different subtypes of cell death and thus the listed features are not necessarily excluding other uncovered features. In addition, different death triggers happening in different tissue cells may also cause variations.

** References.

Bcl-2, B-cell lymphoma 2; TNF, tumor necrosis factor; RIPK, receptor-interacting serine/threonine-protein kinase; MLKL, Mixed lineage kinase domain-like; IKK, I-kappaB-alpha kinase; TBK1, TANK-binding kinase 1; IL-1, interleukin-1; GSDMD, gasdermin D; ACSL4, acyl-CoA synthetase long chain family member 4; POR, NADPH-cytochrome P450 reductase; CYB5R1, NADH-cytochrome b5 reductase; EM, electron microscope.

The formation of plasma membrane pores resulting in dysfunctional ion fluxes, intact but swollen mitochondria with reduced matrix density and collapsed cristae, a peculiar form of chromatin condensation and intact nuclei, and cell lysis are characteristic features of pyroptosis (34–38). Pyroptosis is a highly inflammatory form of cell death that is commonly observed with infection by intracellular pathogens and functions as part of the antimicrobial immune responses (35, 39). The formation of a large supramolecular complex called the inflammasome in response to intracellular danger signals is a hallmark of pyroptosis and mitochondria is a major organ regulating pyroptosis and metabolism (40). In the inflammasome, the activation signal triggers caspase signaling pathways (involving caspase-1/4/5 in humans and caspase-11 in mice; these caspases are different from those involved in apoptosis) and results in the cleavage of pro-interleukin (IL)-1β, pro-IL-18 and gasdermin D (GSDMD), a pore-forming protein (21, 37). The formation of pores then disrupts the cell membrane and releases intracellular molecules such as high-mobility group box 1 (HMGB1), ATP, DNA, and proinflammatory cytokines, which then perpetuate the
causing the accumulation of ROS and the execution of ferroptosis. A detailed review of the different subtypes of cell death in endocrine diseases has been reported in a sophisticated manner by Tonnus et al. (21).

**Dysregulated Iron Metabolism and Oxidative Responses in Ferroptosis**

Iron is critical for the survival and reproduction of all mammals. Under physiological conditions, most iron is contained in red blood cells or forms a transferrin complex (Tf-Fe^{3+}) that circulates in the bloodstream to supply oxygen to the tissue cells from red blood cells (48). Aging red blood cells are undergoing phagocytosis mainly by macrophages, and hemoglobin-derived iron must be recycled back to the circulation for utilization by erythropoietic cells for hemoglobin synthesis. Both ferrous (Fe^{2+}) and ferric (Fe^{3+}) iron integrated within iron-sulfur (Fe-S) clusters, hemoproteins and ribonucleotide reductases mediate various biological functions, such as maintenance of the electron transport chain in the mitochondria, cellular respiration, energy production, and DNA replication and repair (49). Furthermore, iron is a crucial regulator in resuming the functions of enzymes such as catalases, peroxidases, lipoxygenases, cyclooxygenases, and nitric oxide synthases (11). Given that the bioavailability of iron is low under physiological conditions and that iron is important for commensal and pathogenic bacteria to grow, the host coordinates immune mechanisms to limit the accessibility of iron to bacterial invaders and fight against bacterial infection (50).

Iron as an electron carrier also functions as a redox catalyst in the Fenton and Haber-Weiss reactions, resulting in the generation of ROS (51). In response to oxidative stress, various forms of ROS, including superoxide radicals, hydrogen peroxide, hydroperoxyl radicals, hydroxyl radicals and lipid-associated ROS (such as hydroperoxides, peroxyl radicals and alkoxyl radicals), and iron or iron-containing complexes are generated and participate in the formation or decomposition of ROS (52, 53). To counteract oxidative stress, iron must lose electrons to undergo the necessary chemical reactions. Thus, because iron is involved in various reactions to maintain body homeostasis, the mechanisms of maintaining cellular iron levels are critical, and excess intracellular iron triggered by exaggerated oxidative stress will be toxic and cause damage to proteins, DNA and the plasma membrane (49, 51, 54). As one of the recognized effects, the dysregulation of iron metabolism may lead to the iron-dependent accumulation of lethal lipid peroxides in the phospholipid bilayer of the plasma membrane, a mechanism contributing to ferroptosis (4).

The cellular homeostatic mechanisms preventing damage to the cell membrane from lipid peroxides occur via glutathione peroxidase 4 (Gpx4), a selenoenzyme responsible for catalyzing the reduction of oxidized biolipids that converts toxic lipid hydroperoxides into nontoxic lipid alcohols through its cofactor glutathione (GSH) (55–58) (Figure 1). Inside the cell, cystine is reduced to cysteine and then cysteine is used by the enzymes c-glutamyl cysteine synthetase and glutathione synthetase for the synthesis of GSH (59, 60). One molecule of cystine, a predominant extracellular form of cysteine, crosses the plasma membrane in exchange for one molecule of glutamate through a cystine-glutamate antiporter (system Xc”) (61). This cystine/glutamate transporter system also plays a critical role in maintaining intracellular glutathione levels and the redox balance in the extracellular space. The expression of system Xc" is regulated by the nrf2-keap1 pathway (nrf2, nuclear factor E2-related factor-Kelch-like ECH-associated protein 1) (62, 63) and is increased under oxidative stress (64). Given that the cellular cystine/cysteine/GSH/Gpx4 axis is an important pathway to protect cells from undergoing ferroptosis (9), any events triggering oxidative stress or generating inhibitory events on the cystine-glutamate antiporter (system Xc”) by increasing the level of glutamate or an exogenous stimulant, such as sulfasalazine, can deplete intracellular GSH, reduce Gpx4 substrate availability and disrupt the axis (4). Collectively, several key factors, including cystine uptake, GSH level, and Gpx4 activity, act as upstream regulators that counteract the iron-dependent generation of lipid peroxidation products and prevent ferroptosis and plasma membrane damage (53). Studies have shown that Gpx4-knockout mice die at the same embryonic stage, and cells from mice with inducible Gpx4 inactivation exhibit 12/15-lipoxygenase-derived lipid peroxidation and apoptosis-inducing factor (AIF)-mediated cell death (58). In addition to showing that neuron-specific Gpx4 depletion results in a neurodegenerative phenotype in mice (58), inducible Gpx4 depletion manifests with a very large amount of renal tubular epithelial cell death that leads to acute renal failure and early death in mice (5).

While inhibition of system Xc"-mediated cystine uptake is sufficient for erastin-induced ferroptosis, it may not be necessary to execute ferroptosis given that RSL3-induced ferroptosis shares similar patterns with erastin-induced ferroptosis, which does not inhibit cystine uptake. How the increased iron load induces ferroptosis remains unclear because H_{2}O_{2} treatment also results in iron-catalyzed ROS production; however, H_{2}O_{2}-induced cell death patterns are different from ferroptosis (4). Indeed, up-to-date research has still not disclosed the signals that ignite message transmission leading to ferroptosis (65). In addition, it remains unclear whether the phenotypic changes seen in ferroptotic cells are a consequence of the disruption of the plasma membrane due to extensive lipid peroxidation or a consequence of downstream signaling-mediated events. More comprehensive reviews about the mechanisms and processes involved in ferroptosis can be found elsewhere (57, 66).

**Ferroptosis in Autoimmune Diseases**

**Ferroptosis in SLE**

Systemic lupus erythematosus is a unique autoimmune disease triggered by the overproduction of a variety of autoantibodies directed against cellular components from the nucleus, cytoplasm and membrane, and the resulting formation and...
deposition of immune complexes in different tissues and organs can cause organ damage. The induction and exaggeration of cell death and impairment of the removal or uptake of dead cells by macrophages increases the opportunity to expose intracellular contents to the immune system and induce immune responses (67, 68). In the hemopoietic system, a decrease in immune cells, such as neutrophils, lymphocytes, red blood cells and platelets, is commonly observed in patients with SLE, although the mechanisms are not exactly clear. Studies have shown that peripheral blood neutrophils collected from pediatric SLE patients tend to die spontaneously and more quickly than healthy neutrophils in cell culture (69). A significant event accompanying neutrophil death is the induction of neutrophil extracellular trap (NET) release, which activates Toll-like receptors and induces the generation of ROS. NET is also a potent stimulant that induces the release of type I interferon (IFN) from plasmacytoid dendritic cells, which causes intense inflammatory reactions (69).

The mechanisms of cell death in neutrophils were recently demonstrated to be through ferroptosis manifesting with morphological changes, including vacuole formation, and the disappearance of cristae and increased membrane density in mitochondria (70). Reduced expression of Gpx4 in neutrophils can be readily detected in patients with SLE compared to healthy controls (Table 2). While treatment with serum immunoglobulin IgG from SLE patients or IFN-α causes a reduction in Gpx4 and neutrophil death, blockade of IFN-α resumes the survival of neutrophils (Figure 1). Treatment with ferroptosis inhibitors such as liproxstatin-1, a potent spiroquinoxalinamine derivative, and deferoxamine, an intracellular iron chelator, could attenuate neutrophil death induced by SLE patient serum. By analyzing the regulation of Gpx4 expression, the authors observed a conserved binding site in the Gpx4 promoter for cAMP-responsive element modulator α (CREMα), a tissue-specific transcriptional repressor. Further studies revealed increased nuclear accumulation and increased binding of CREMα to the Gpx4 promoter in SLE neutrophils, a phenomenon reproducibly detected by treating neutrophils from healthy individuals with SLE serum or IFN-α. The results are supportive for the observations of activated Ca^{2+}/calmodulin-
TABLE 2 | Summary of study findings of ferroptosis in autoimmune diseases.

| Source of the findings | SLE (70)* | RA (81, 83) | IBD (90-100) |
|------------------------|-----------|-------------|--------------|
| **Methods of studies** | Analyzing Gpx4 expression and neutrophil death and SLE parameters such as proteinuria and anti-ds DNA antibodies levels | Administering imidazole ketone erastin or RSL3 and examining synovial fibroblasts subsets and macrophages | Mice fed with PUFA-enriched diet like AA, or treated with DSS and examination on lipid peroxidation, IL-6 and CXCL1 production. Ferroptosis of IECs from IBD patients and PUFA-fed Gpx4+/−/IEC mice. Dietary AA induced production of IL-6 and CXCL1. Treatment with ferrostatin-1 attenuated DSS-induced colitis. Dietary AA administration reduced expression and enzymatic activity of Gpx4 and caused lipid peroxidation and ferroptosis in IECs. |
| **Observations** | Gpx4 haplotype deficiency mice developed features characteristic of lupus, such as the production of anti-ds DNA antibodies, skin lesions and proteinuria. Neutrophils underwent ferroptosis in SLE patients. | Macrophages released TNF-α to increase GSH biosynthesis and mediated protection of FA-Px-positive synovial fibroblasts from undergoing ferroptosis. | IECs in colonic mucosal samples from IBD patients and mice with DSS-induced colitis or preserving one Gpx4 allele. |
| **Mechanisms** | IFN-α or SLE serum suppressed Gpx4 expression by increasing binding of CREMα to the Gpx4 promoter. | Decrease of synovitis severity and prevention of arthritis and joint damage by induction of ferroptosis. TNF-α was protective against ferroptosis. | |

*, references.
CIA, collagen-induced arthritis; anti-ds DNA, anti-double stranded DNA; IFN-α, interferon-alpha; DSS, dextran sodium sulfate; GSH, glutathione; RSL3, RAS synthetic lethal 3; CREMα, cAMP-response element modulator alpha; TNF-α, tumor necrosis factor-alpha; IEC, intestinal epithelial cells; IL-6, interleukin-6; CXCL1, chemokine (C-X-C motif) ligand 1; PUFA, polyunsaturated fatty acids; AA, arachidonic acid.

Table: Summary of study findings of ferroptosis in autoimmune diseases.

- **Source of the findings**: Mice with myeloid-specific Gpx4 haplotype deficiency and SLE patients
- **Methods of studies**: Analyzing Gpx4 expression and neutrophil death and SLE parameters such as proteinuria and anti-ds DNA antibodies levels.
- **Observations**: Gpx4 haplotype deficiency mice developed features characteristic of lupus, such as the production of anti-ds DNA antibodies, skin lesions and proteinuria. Neutrophils underwent ferroptosis in SLE patients.
- **Mechanisms**: IFN-α or SLE serum suppressed Gpx4 expression by increasing binding of CREMα to the Gpx4 promoter.

Ferroptosis is a form of cell death that is induced by the accumulation of lipids and proteins, leading to the formation of reactive oxygen species (ROS). In SLE, ferroptosis can play a role in the development of the disease. The expression of Gpx4, a key enzyme in the peroxidase cycle, was found to be reduced in SLE patients, leading to a decreased ability to detoxify ROS. This can result in the accumulation of lipid peroxidation products, such as hydroxyalkenals, which can damage cellular components and contribute to the pathogenesis of SLE.

In a study by Lai et al. (2022), the role of ferroptosis in SLE was reviewed. The authors found that neutrophil ferroptosis can be blocked by the administration of neutrophil ferroptosis inhibitors, which can lead to improved outcomes in SLE patients. Furthermore, the study suggested that serum transferrin concentrations are inversely correlated with the presence of SLE, indicating that iron availability may play a role in the development of the disease.

In summary, ferroptosis plays a significant role in the pathogenesis of SLE, and understanding its mechanisms can provide new targets for therapeutic intervention.
Consistent with the notion that suppression of synovial fibroblast ferroptosis is one of the mechanisms involved in maintaining the inflammation status in joints, administration of the lipid peroxidation and ferroptosis inducer imidazole ketone erastin (IKE) resulted in a decrease in synovitis severity and prevented the development of arthritis and joint damage in CIA mice (81). Experiments showed that IKE treatment selectively reduced the population of fibroblast activation protein-α (FAPα)-positive synovial fibroblasts that were undetectable under noninflammatory conditions but significantly increased in the inflamed synovium of CIA mice (81). Interestingly, treatment with the Gpx4 inhibitor RSL3 specifically increased cell death in fibroblast activation protein-α (FAP)α+ fibroblasts but not in macrophages, endothelial cells, T cells or B cells (81). The increased sensitivity to RSL-induced cell death in synovial fibroblasts prepared from inflamed synovial fluid compared to fibrocytes obtained from peripheral blood suggests that certain environmental factors inside inflamed joints are responsible for preventing synovial fibroblasts from undergoing ferroptosis and producing lipid ROS. Furthermore, a higher number of surviving FAPα+ fibroblasts in synovial areas were close to macrophages, suggesting that macrophages may protect FAPα+ fibroblasts from lipid peroxidation and ferroptosis induced by IKE treatment in CIA mice. By applying single-cell RNA sequencing, researchers identified different subsets of FAPα+ fibroblasts in the synoviums of RA patients and CIA mice. The ferroptosis-sensitive subset expressed higher levels of genes related to extracellular matrix formation and remodeling, and the ferroptosis-resistant subset expressed higher levels of genes associated with cellular proliferation (81).

The protective effect provided by macrophages to ferroptosis-resistant FAPα+ fibroblasts in the synovium is likely due to the enriched production of TNF-α, a major proinflammatory cytokine that is mainly produced by macrophages and is a major contributor to the pathogenesis of RA (81, 82) (Figure 2). Genetic analysis of synovial fibroblasts from RA patients revealed that long-term treatment with TNF resulted in the increased expression of cell proliferation genes and the decreased expression of extracellular matrix-related genes (81). The dissection of cells with different lineages from RA hyperplastic synovium to examine the interplay among fibroblasts, macrophages, and TNF was then carried out. The results confirmed the existence of fibroblast subsets with distinct ferroptosis sensitivities that is likely due to reception of signaling of TNF released from activated macrophages (81). TNF-mediated protection against ferroptosis was also observed in human synovial fibroblasts treated with the ferroptosis inducers IKE and RSL3; however, the TNF-conferred protection from undergoing ferroptosis in fibroblasts was only observed at low doses and not at high doses (81). Treatment with IKE resulted in the depletion of GSH while TNF administration reversed this effect and increased the GSH levels in synovial fibroblasts.

![Figure 2](image.jpg)
Treatment with TNF did not affect iron availability, whereas it did enhance the expression of several regulators associated with GSH biosynthesis, including solute carrier family 7 member 11 (SLC7A11), a functional subunit of system Xc- and a molecule responsible for the generation of intracellular GSH, GCLC (a glutamate-cysteine ligase regulatory subunit) and GCLM (a glutamate-cysteine ligase catalytic subunit) (81). It would also be interesting to know whether the therapeutic benefits of anti-TNF biologics may be attributed in part to blocking the TNF-mediated protection of synovial fibroblasts in the inflamed joints of RA patients.

The ferroptosis-protective effects of TNF on synovial fibroblasts appear to be specific because the effects were not observed for other proinflammatory cytokines, such as IL-6, which is also highly induced in inflamed joints in RA. In contrast, under similar conditions, IL-6 treatment increased intracellular iron levels, decreased the expression of solute carrier family 40 member 1 (SLC40A1) and ferritin and yet without changing the GSH levels, and resulted in the sensitization of fibroblasts to ferroptosis (81). This study further demonstrated that the combination of a low dose of IKE to deprive cystine and a low dose of the TNF blocker etanercept provided a synergistic effect to reduce p-NF-KB, GCLM, and GCLC expression by inducing fibroblast ferroptosis in CIA mice (81).

Furthermore, a reduction in ferroptosis accompanied by a decrease in acyl coenzyme A synthetase long chain 4 (ACSL4) and increases in Gpx4, ferritin heavy chain 1 and SLC7A11 was observed in the synoviums and synovial fibroblasts from RA patients compared to those from healthy controls (81). RNA-Seq analysis revealed that glycine could regulate the ferroptosis pathway by upregulating the S-adenosylmethionine (SAM) concentration and downregulating Gpx4 expression by inducing SAM-mediated Gpx4 promoter methylation in RA synovial fibroblasts (83). Altogether, these studies (81, 83) suggest that inducing ferroptosis in proliferating synovial fibroblasts in the inflamed joints of RA patients may be therapeutically beneficial. Regarding this, the older anti-RA medication auranoftin can also serve as an example. Auranoftin contains gold and was used to treat patients with RA (84); however, because of its high toxicity and the great advancements in modern therapeutics, this medication is no longer used to treat patients with RA, although it remains a potential treatment for other diseases (85). Given that high-dose auranoftin treatment (25 mg/kg) caused lipid peroxidation and ferroptosis by inhibiting thioredoxin reductase (TXNRD) activity, treatment with a low dose (5 mg/kg) potently induced the expression of hepcidin by activating the bone morphogenetic protein (BMP)/Smad and IL-6/Janus kinase (Jak)2/signal transducer and activator of transcription (Stat)3 pathways, leading to reduced serum iron, transferrin saturation and inhibition of ferroptosis in mice (86). Aiming to regulate cellular ferroptosis while maintaining tolerable drug toxicity, choosing a therapeutic dose of auranoftin appears to be critical. Given the critical process of ROS production in RA pathogenesis, ferroptosis-targeted therapy has been proposed (87, 88).

### Ferroptosis and Inflammatory Bowel Diseases

As the intestinal epithelium is a critical organ for nutrient absorption, cell death here must be carefully regulated, and any interference with cell regeneration or cell death processes may cause pathologies. The inflammatory bowel diseases Crohn’s disease (CD) and ulcerative colitis (UC) manifest with more cell death in the intestine and colon due to chronic inflammation. Several cell death subtypes have been shown to participate in causing chronic intestinal inflammation (89). Over-supplementation of iron increases its deposition in the intestine, resulting in excessive production of ROS and inducing intestinal inflammation in dextran sodium sulfate (DSS)-induced colitis in mice, an animal model of IBD (90, 91) (Figure 3). Indeed, iron supplementation may have either beneficial or detrimental effects by influencing the gut microbiota (92). Additionally, supported by studies showing the crucial roles of ROS and iron in the progression of UC (93), colonic mucosal specimens from UC patients expressed genetic patterns compatible with those in ferroptosis (94). Similar features were also observed in experimental colitis in mice treated with DSS (94). In addition, treatment with the ferroptosis inhibitor ferrostatin-1 attenuated experimental colitis induced by DSS administration (94).

Polyunsaturated fatty acids (PUFAs), especially arachidonic acid (AA) and linoleic acid, preserve highly oxidizable methylene groups that bridge two double bonds and are the two major substrates for lipid peroxidation (66, 95). Compared to the less reactive monounsaturated and saturated fatty acids, PUFAs are ideal targets for attack by ROS, and accumulated cytosolic and lipid ROS serve as potent triggers to oxidize PUFAs to generate lipid peroxides, thus inducing ferroptosis (10, 96). The oxidation of PUFAs can be regulated by either an enzymatic reaction, such as a lipoxygenase-mediated reaction, or a nonenzymatic reaction, such as a Fenton-type reaction, in the plasma membrane (57, 97). Exposure to a PUFA-enriched Western diet induced lipid peroxidation and intestinal inflammation in mice with the specific deletion of one Gpx4 allele, which resulted in an ~50% reduction in Gpx4 mRNA and protein levels in the intestinal epithelial cells (IECs) of both the large and small intestines compared to wild-type mice (97). In addition, the oral uptake of AA resulted in neutrophil infiltration in the small intestines of iron-primed mice with IECs deficient in one Gpx4 allele (97). Certain features, including neutrophil infiltration into mucosal and submucosal lesions, epithelial injury, crypt hyperplasia, and granuloma-like accumulation of inflammatory cells reminiscent of certain small intestinal CD characteristics, were observed in PUFA WD-fed Gpx4+/-IEC mice (97). In addition, epithelial lipid peroxidation and the increased expression of chemokine (C-X-C motif) ligand 1 (CXCL1) were noted in the lesions. However, there was no evident IEC death in Gpx4+/-IEC mice fed a PUFA-enriched Western diet, suggesting that cell death was not absolutely required for PUFA-induced intestinal inflammation in Gpx4+/-IEC mice (97). Ferric iron promoted lipid peroxidation and AA-induced IL-6 and CXCL1 production in siGpx4 IECs, whereas treatment with the iron chelator deferoxamine or the lipid peroxidation scavenger ferrostatin-1
and α-tocopherol or inhibition of lipoxygenases (LOX) reduced IL-6 and CXCL1 production in AA-stimulated siGpx4 IECs (97). The data suggested that iron availability is critical to control PUFA-induced lipid peroxidation and cytokine production in IECs with reduced Gpx4 levels and enzymatic activity.

In patients with active UC, AA accumulates in the colonic mucosa (98), which correlates with evidence showing that increased uptake of dietary AA increases the risk of UC (99). Since ACSL4, an enzyme that ligates long PUFAs to coenzyme A, esterifies AA into phospholipids to facilitate peroxidation (7, 100), subsequent experiments demonstrated that AA-induced IL-6 and CXCL1 production was blocked in Acsl4-deleted siGpx4 IECs (97). In parallel, AA stimulation induced lipid peroxidation, which was not inhibited by Acsl4 deletion in siGpx4 IECs (97). In addition, AA stimulation induced lipid peroxidation, which was not inhibited by Acsl4 deletion in siGpx4 IECs. These results indicate that ACSL4 and Gpx4 may differentially regulate AA-induced cytokine responses and lipid peroxidation, respectively (97).

Perspective and Potential of Targeting Ferroptosis for Autoimmune Disease Therapeutics

As indicated, how ferroptosis is initiated and executed remains largely unclear. Several inducers/sensitizers such as erastin or its analogues, drugs like sulfasalazine, sorafenib and statins, and high concentration of extracellular glutamate could serve to trigger ferroptosis (57). However, there is no specific receptors involved in response to these potential ferroptosis inducers/sensitizers (57). Our current understanding about ferroptosis is that ferroptosis is induced by the dysregulation of molecules critically controlling redox systems and preventing lipid peroxidation (66). Different tissue cells may show differential sensitivity to ferroptosis and cancer cells seem to be very sensitive to lipid peroxidation (21). As an example, in SLE, ferroptosis happened only in neutrophils but not in monocytes or lymphocytes, a phenomenon likely due to the relatively lower levels of Gpx4 in neutrophils compared to that in monocytes and lymphocytes in healthy people (70).
have been identified. By using a synthetic lethal CRISPR-Cas9 screen, the researchers identified ferroptosis suppressor protein 1 (FSP1), also known as apoptosis-inducing factor mitochondria associated 2 (AIFM2), as a potent ferroptosis-resistance molecule that effectively prevented ferroptosis in a GSH-independent manner. To be effective, FSP1 must be recruited to the plasma membrane via its myristylation binding motifs and mediate oxidoreductase activity to reduce coenzyme Q_{10} (CoQ), a lipophilic radical-trapping antioxidant halting the propagation of lipid peroxides (102, 103). Applying RNA-seq approaches, Brown et al. identified a pentaspanin protein prominin 2, a lipid dynamic regulator, that could promote the formation of ferritin-containing multivesicular bodies and exosomes and mediate transportation of iron out of the cell to inhibit ferroptosis (104). We refer the readers to an excellent review by Stockwell et al. (57) regarding the inducers, inhibitors and genes involved in ferroptosis as well as its association with metabolism.

In terms of therapeutics, targeting ferroptosis for the treatment of autoimmune diseases appears to be complicated because ferroptotic processes occurring in different diseases and different tissues may have different impacts. As discussed above, while the induction of ferroptosis in the synovium of patients with RA may be therapeutically beneficial, cell survival preservation and ferroptosis inhibition or prevention may be favorable for treating diseases such as IBD and SLE. In addition, given that the factors that induce ferroptosis in these different autoimmune diseases remain largely unclear, cytokines such as TNF-α and IFN-α regulate ferroptosis in different manners and contribute in various ways to disease pathogenesis (70, 81). While IL-6 may be detrimental by causing ferroptosis in IECs (97), the ferroptosis-inducing effects of IL-6 may be beneficial for controlling joint inflammation in RA patients (81). Furthermore, as the example in SLE patients shows, under exposure to the same extracellular conditions, IFN-α-induced ferroptosis occurred only in neutrophils but not in lymphocytes or monocytes (70). All these clues make targeting ferroptosis for therapeutic purposes even more complicated. It is evident that scientific societies need more studies to examine ferroptosis events and the underlying mechanisms that occur in autoimmune diseases. Whether a beneficial or a detrimental outcome is achieved by manipulating cellular ferroptosis will be dependent on the results from animal studies and clinical trials.

Practically, there are many different approaches to block ferroptosis: pharmacologically using thiazolidinediones to inhibit ACSL4 activity, restoring the level of the key ferroptosis regulator Gpx4, administering ferroptosis-specific inhibitors such as ferrostatins and liproxstatins, preventing lipid peroxidation with supplementation of fatty acids, iron chelators and antioxidants, or modulating metabolic pathways (53). As an example, one antirheumatic drug, sulfasalazine, is a ferroptosis inducer. Sulfasalazine suppresses GSH biosynthesis and inhibits system Xc to induce ferroptosis in tumors (4, 105). However, it remains unclear whether the pro-ferroptotic effects of sulfasalazine may account for the observed effects in autoimmune disorders such as RA and spondyloarthritis. Given that ER stress was shown to mediate IEC ferroptosis in colonic mucosal specimens from UC patients, inhibiting ER stress with GSK2606414 could prevent IECs from undergoing ferroptosis and reduce the severity of experimental colitis in mice (94). Furthermore, treatment with OTSSP167, a MELK-selective inhibitor, significantly inhibited ferroptosis and reduced DSS-induced colitis in mice by suppressing the protein kinase B (AKT)/IKK/p65 and extracellular signal-regulated kinase (ERK)/IKK/p65 signaling cascades (106).

Knowing that apoptosis and other cell death subtypes are also observed in IECs from patients with UC and CD (107–111), how these different cell death pathways interact with one another and the consequences of these interactions in autoimmune diseases are interesting topics to investigate. In addition, how cellular mechanisms regulate these different cell death subtypes to either maintain homeostasis or counteract threats from extracellular stress or pathogens is largely unknown and deserves further investigation. Altogether, studies targeting ferroptosis events, effects, mechanisms, and therapeutics will be hot topics to pursue in the field of autoimmune diseases in the future.

**AUTHOR CONTRIBUTIONS**

Writing—original draft preparation, BL. and J-HL. Writing—review and editing, BL, C-YW, C-HW, S-FL and J-HL. Supervision, J-HL. Funding acquisition, J-HL. All authors contributed to the article and approved the submitted version.

**FUNDING**

This work was supported by grants from the Ministry of Science and Technology (MOST 110-2314-B-182A-127-MY3) and Chang Gung Memorial Hospital (CMRPG1M0021), Taiwan, R.O.C.

**REFERENCES**

1. Dolma S, Lessnick SL, Hahn WC, Stockwell BR. Identification of Genotype-Selective Antitumor Agents Using Synthetic Lethal Chemical Screening in Engineered Human Tumor Cells. *Cancer Cell* (2003) 3(3):285–96. doi: 10.1016/s1535-6108(03)00050-3

2. Yang WS, Stockwell BR. Synthetic Lethal Screening Identifies Compounds Activating Iron-Dependent, Nonapoptotic Cell Death in Oncogenic-RAS-Harboring Cancer Cells. *Chem Biol* (2008) 15(3):234–45. doi: 10.1016/j.chembiol.2008.02.010

3. Yagoda N, von Rechenberg M, Zagajnar E, Bauer AJ, Yang WS, Fridman DJ, et al. RAS-RAF-MEK-Dependent Oxidative Cell Death Involving Voltage-Dependent Anion Channels. *Nature* (2007) 447(7146):864–6. doi: 10.1038/nature05859

4. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. *Cell* (2012) 149(5):1060–72. doi: 10.1016/j.cell.2012.03.042

5. Friedmann Angeli JP, Schneider M, Proneth B, Tyurina YY, Tyurin VA, Hammond VJ, et al. Inactivation of the Ferroptosis Regulator Gpx4 Triggers...
Acute Renal Failure in Mice. *Nat Cell Biol* (2014) 16(12):1180–91. doi: 10.1038/nclb30646

6. Kim SE, Zhang L, Ma K, Rieger M, Chen F, Ingold I, et al. Ultrasmall Nanoparticles Induce Ferroptosis in Nutrient-Deprived Cancer Cells and Suppress Tumour Growth. *Nat Nanotechnol* (2016) 11(11):977–85. doi: 10.1038/nnano.2016.164

7. Doll S, Pernth B, Tyurina YP, Panzilius E, Kobayashi S, Ingold I, et al. ACSL4 Dictates Ferroptosis Sensitivity by Shaping Cellular Lipid Composition. *Nat Chem Biol* (2017) 13(1):91–8. doi: 10.1038/nchembio.2239

8. Chen X, Kang R, Kroemer G, Tang D. Organelle-Specific Regulation of Ferroptosis. *Cell Death Differ* (2021) 28(10):288–56. doi: 10.1038/s41418-021-00859-z

9. Jiang X, Stockwell BR, Conrad M. Ferroptosis: Mechanisms, Biology and Role in Disease. *Nat Rev Mol Cell Biol* (2022) 22(4):266–82. doi: 10.1038/s41580-020-00324-8

10. Xu C, Liu Z, Xiao J. Ferroptosis: A Double-Edged Sword in Gastrointestinal Disease. *Int J Mol Sci* (2021) 22(22):ijms22212403. doi: 10.3390/ijms22212403

11. Rodriguez R, Schreiber SL, Conrad M. Persister Cancer Cells: Iron Addiction and Vulnerability to Ferroptosis. *Mol Cell* (2022) 82(4):728–40. doi: 10.1016/ j.molcel.2021.12.001

12. Nagata S. Apoptosis and Clearance of Apoptotic Cells. *Annu Rev Immunol* (2018) 36:489–517. doi: 10.1146/annurev-immunol-042717-093549

13. Guo C, Fu R, Zhou M, Wang S, Huang Y, Hu H, et al. Pathogenesis of Lupus Nephritis: RIP3 Dependent Necroptosis and NLRP3 Inflammasome Activation. *J Autoimmun* (2019) 103:102286. doi: 10.1016/j.jaut.2019.05.015

14. Fan H, Liu F, Dong G, Ren D, Xu Y, Dou J, et al. Activation-Induced Necroptosis Contributes to B-Cell Lymphopenia in Active Systemic Lupus Erythematosus. *Cell Death Dis* (2014) 5:e1146. doi: 10.1038/cddis.2014.375

15. Zhao J, Jiang P, Guo S, Schrodi SJ, He D. Apoptosis, Autophagy, NETosis, Necroptosis, and Pyroptosis Mediated Programmed Cell Death as Targets for Innovative Therapy in Rheumatoid Arthritis. *Front Immunol* (2021) 12:609806. doi: 10.3389/fimmu.2021.609806

16. Wang B, Li H, Wu J, Cai ZY, Li B, Ni H, et al. Gut Stem Cell Necroptosis by Genomic Instability Triggers Bowel Inflammation. *Nature* (2020) 580(7803):386–90. doi: 10.1038/s41586-020-2127-x

17. Chen X, Liu G, Yuan Y, Wu G, Wang S, Yuan L. NEK7 Interacts With NLRP3 to Modulate the Pyroptosis in Inflammatory Bowel Disease via NF-kappaB Signaling. *Cell Death Dis* (2019) 10(12):906. doi: 10.1038/s41419-019-1117-5

18. Lichtenberger GS, Flavell RA, Alexopoulou L. Innate Immunity and Apoptosis in IBD. *Inflamm Krb Bowel Dis* (2004) 10 Suppl 1:S58–62. doi: 10.1007/s00291-004-0011-2

19. Hu CL, Nydes M, Shanley KL, Morales Pantoja IE, Howard TA, Bizzozero OA. Reduced expression of the Ferroptosis Inhibitor Glutathione Peroxidase-4 in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. *J Neurochem* (2019) 148(3):326–39. doi: 10.1111/jnc.14604

20. Duprez L, Wirawan E, Vanden Berge T, Vandenabeele P. Major Cell Death Pathways at a Glance. *Microbes Infect* (2009) 11(13):1050–62. doi: 10.1016/j.micinf.2009.08.013

21. Tonnon W, Belavgeni A, Beuschlein F, Eisenhofer G, Fassnacht M, Kroemer H, et al. The Role of Regulated Necrosis in Endocrine Diseases. *Nat Rev Endocrinol* (2021) 17(8):497–510. doi: 10.1038/s41574-021-00499-w

22. Peter ME. Programmed Cell Death: Apoptosis Meets Necrosis. *Nature* (2011) 471(7388):310–2. doi: 10.1038/471310a

23. Roberts JZ, Crawford N, Longley DB. The Role of Ubiquitination in Apoptosis and Necroptosis. *Cell Death Differ* (2022) 29(2):272–84. doi: 10.1038/s41418-021-00922-9

24. Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial Outer Membrane Permeabilization During Apoptosis: The Innocent Bystander Scenario. *Cell Death Differ* (2006) 13(8):1396–402. doi: 10.1038/sj.cdd.4401963

25. Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M, et al. Two Distinct Pathways Leading to Nuclear Apoptosis. *J Exp Med* (2000) 192(4):751–80. doi: 10.1084/jem.20001571

26. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A Basic Biological Phenomenon With Wide-Ranging Implications in Tissue Kinetics. *Br J Cancer* (1972) 26(4):239–57. doi: 10.1038/bjc.1972.33
Lai et al. Ferroptosis and Autoimmune Diseases

46. Chen X, Comish PB, Tang D, Kang R. Characteristics and Biomarkers of Ferroptosis. Front Cell Dev Biol (2021) 9:637162. doi: 10.3389/fcel.2021.637162
47. Yan B, Ai Y, Sun Q, Ma Y, Cao Y, Wang J, et al. Membrane Damage During Ferroptosis Is Caused by Oxidation of Phospholipids Catalyzed by the Oxidoreductases POR and CYB5R1. Mol Cell (2021) 81(2):355–69.e10. doi: 10.1016/j.molcel.2020.11.024
48. Lawen A, Lane DJ. Mammalian Iron Homeostasis in Health and Disease: Uptake, Storage, Transport, and Molecular Mechanisms of Action. Antioxid Redox Signal (2013) 18(18):2473–507. doi: 10.1089/ars.2011.4271
49. Muckenhalter MU, Rivella S, Hentze MW, Galy B. A Red Carpet for Iron Metabolism. Cell (2017) 168(3):344–61. doi: 10.1016/j.cell.2016.12.034
50. Golonka R, Yeoh BS, Vijay-Kumar M. The Iron Tug-Of-War Between Bacterial Siderophores and Innate Immunity. J Innate Immun (2019) 11(3):249–62. doi: 10.1159/000494627
51. Zhang C. Essential Functions of Iron-Requiring Proteins in DNA Replication, Repair and Cell Cycle Control. Protein Cell (2014) 5(10):750–60. doi: 10.1007/s13238-014-0083-7
52. Gutteridge JM, Halliwell B. Iron Toxicity and Oxygen Radicals. Baillieres Clin Haematol (1989) 2(2):195–256. doi: 10.1016/s0950-3536(89)80017-4
53. Doll S, Conrad M. Iron and Ferroptosis: A Still Ill-Defined Liaison. JUBMB Life (2017) 69(6):423–34. doi: 10.1002/jub.1616
54. Pantopoulos K, Porwal SK, Tartakoff A, Devireddy L. Mechanisms of Mammalian Iron Homeostasis. Biochemistry (2012) 51(29):7505–24. doi: 10.1016/j.biochem.2012.05.021
55. Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. The Chemical Basis of Ferroptosis. Cell (2015) 161(5):629–43. doi: 10.1016/j.cell.2015.03.037
56. Ursini F, Maiorino M, Gregolin C. The Selenoenzyme Phospholipid Glutathione Peroxidase 4 Senses and Translates Oxidative Stress Into 12/15-Lipoxygenase Dependent- and AIF-Mediated Cell Death. Cell Metab (2014) 15(12):317–31. doi: 10.1016/j.cmet.2013.12.010
57. Viswanathan VS, et al. Regulation of Ferroptotic Cancer Cell Death by Glutathione Peroxidase 4-Dependent- and AIF-Mediated Cell Death. Cell Metab (2015) 22(5):777–87. doi: 10.1016/j.cmet.2015.09.006
58. Vanarsa K, Ye Y, Han J, Xie C, Mohan C, Wu T. Inflammation Associated Anemia and Ferritin as Disease Markers in SLE. Arthritis Rheum (2012) 14(4):R182. doi: 10.1002/art.34012
59. Phull AR, Nasir B, Haq JU, Kim SJ. Oxidative Stress, Consequences and ROS Mediated Cellular Signaling in Rheumatoid Arthritis. Chemico-biol Interact (2018) 281:121–36. doi: 10.1016/j.cbi.2017.12.024
60. Wu J, Feng Z, Chen L, Li Y, Bian H, Geng J, et al. TNF Antagonist Sensitizes Synovial Fibroblasts to Ferroptotic Cell Death in Collagen-Induced Arthritis Mouse Models. Nat Commun (2022) 13(1):676. doi: 10.1038/s41467-021-27948-4
61. Kalliolesi GD, Ivashik LB. TNF Biology, Pathogenic Mechanisms and Emerging Therapeutic Strategies. Nat Rev Rheumatol (2016) 12(1):49–62. doi: 10.1038/nrrheum.2015.169
62. Ling H, Li M, Yang C, Sun S, Zhang W, Zhao L, et al. Glycine Increased Ferroptosis via SAM-Mediated GPX4 Promoter Methylation in Rheumatoid Arthritis. Rheumatol (Oxford) (2022) pii:6524462. doi: 10.1093/rheumatology/keac069
63. Katza WA, Alexander S, Bland JH, Blechman WB, Bluhm GB, Bonebrake RA, et al. The Efficacy and Safety of Auranofin Compared to Placebo in Rheumatoid Arthritis. J Rheumatol Suppl (2002) 81:173–8.
64. Celogato M, Borghese C, Casagrande N, Mongiat M, Kahle XU, Paulitti A, et al. Preclinical Activity of the Repurposed Drug Auranofin in Classical Hodgkin Lymphoma. Blood (2015) 126(11):1394–7. doi: 10.1182/blood-2015-07-660365
65. Yang L, Wang H, Yang X, Wu Q, An P, Jin X, et al. Auranofin Mitigates Systemic Iron Overload and Induces Ferroptosis via Distinct Mechanisms. Signal Transduct Target Ther (2020) 5(1):138. doi: 10.1038/s41392-020-00253-0
66. Xie Z, Hou H, Luo D, An R, Zhao Y, Qiu C. ROS-Dependent Lipid Peroxidation and Reliant Antioxidant Ferroptosis-Suppressor-Protein 1 in Rheumatoid Arthritis: A Covert Clue for Potential Therapy. Inflammation (2021) 44(1):35–47. doi: 10.1007/s10753-020-01338-2
67. Zhao T, Yang Q, Xi Y, Xie Z, Shen J, Li P, et al. Ferroptosis in Rheumatoid Arthritis: A Potential Therapeutic Strategy. Front Immunol (2022) 13:779585. doi: 10.3389/fimmu.2022.779585
68. Gunther C, Neumann H, Neurath MF, Becker C. Apoptosis, Necrosis and Necroptosis: Cell Death Regulation in the Intestinal Epithelium. Gut (2013) 62(7):1062–71. doi: 10.1136/gutjnl-2011-301364
69. Eriksen K, Milde AM, Arslan L, Hgeland L, Gudbrandsen OA, Ulvik RJ, et al. Low-Dose Oral Ferrous Fumarate Aggravated Intestinal Inflammation

Frontiers in Immunology | www.frontiersin.org 12 June 2022 | Volume 13 | Article 916664
in Rats With DSS-Induced Colitis. *Inflamm Bowel Dis* (2005) 11(8):744–8. doi: 10.1097/01.mib.0000174374.83601.86

91. Carrier JC, Agulhon E, Jejeebhoy K, Allard JP. Exacerbation of Dextran Sulfate Sodium-Induced Colitis by Dietary Iron Supplementation: Role of NF-KappaB. *Int J Colorectal Dis* (2006) 21(4):381–7. doi: 10.1007/s00384-005-0011-7

92. Constanthe M, Fragosgo G, Lupien-Meiller J, Calve A, Santos MM. Iron Supplements Modulate Colon Microbiota Composition and Potentiate the Protective Effects of Probiotics in Dextran Sodium Sulfate-Induced Colitis. *Inflamm Bowel Dis* (2017) 23(5):753–66. doi: 10.1097/MIB.000000000001089

93. Biasi F, Leonardiuzzi G, Oteiza PI, Poli G. Inflammatory Bowel Disease: Mechanisms, Redox Considerations, and Therapeutic Targets. *Antioxid Redox Signal* (2013) 19(14):1711–47. doi: 10.1089/ars.2012.4530

94. Xu M, Tao J, Yang Y, Tan S, Liu H, Jiang J, et al. Ferroptosis Involves in Intestinal Epithelial Cell Death in Ulcerative Colitis. *Cell Death Dis* (2020) 11(2):86. doi: 10.1038/s41419-020-2299-1

95. Yin H, Xu L, Porter NA. Free Radical Lipid Peroxidation: Mechanisms and Analysis. *Chem Rev* (2011) 111(10):5944–72. doi: 10.1021/cr200084z

96. Richard D, Kefi K, Barbe U, Baussero P, Visioli F. Polyunsaturated Fatty Acids as Antioxidants. *Pharmacol Res* (2008) 57(6):451–5. doi: 10.1016/j.phrs.2008.05.002

97. Mayr L, Grabher F, Schwarzer J, Reitmeier I, Sommer F, Gehmacher T, et al. Increased Enterocyte Apoptosis in Inflammatory Bowel Disease. *Nature* (2011) 477(7364):335–9. doi: 10.1038/nature10400

98. Nishida T, Miwa H, Shigematsu A, Yamamoto M, Iida M, Fujishima M. Increased Arachidonic Acid Composition of Phospholipids in Colonic Mucosa From Patients With Active Ulcerative Colitis. *Gut* (1987) 28(8):1002–7. doi: 10.1136/gut.28.8.1002

99. de Silva PS, Olsen A, Christensen J, Schmidt EB, Overvaad K, Jeejeebhoy K, et al. An Association Between Dietary Arachidonic Acid, Measured in Adipose Tissue, and Ulcerative Colitis. *Gut* (2003) 46(11):1498–507. doi: 10.1038/sj.gut.3803379

100. Kagan VE, Mao G, Qu F, Angeli JP, Doll S, Croix CS, et al. Oxidized Arachidonic and Adrenic PEs Navigate Cells to Ferroptosis. *Nat Chem Biol* (2017) 13(13):81–90. doi: 10.1038/nchembio.2238

101. Jostins L, Ripke S, Weerima RK, Duerr RH, McGovern DP, Hui KY, et al. Host-Microbe Interactions Have Shaped the Genetic Architecture of Inflammatory Bowel Disease. *Nature* (2012) 491(7422):119–24. doi: 10.1038/nature11582

102. Bersuher K, Hendricks JM, Li Z, Magtanong L, Ford B, Tang PH, et al. The CoQ Oxidoreductase FSP1 Acts Parallel to GPX4 to Inhibit Ferroptosis. *Nature* (2019) 575(7784):688–92. doi: 10.1038/s41586-019-1705-2

103. Doll S, Freitas FP, Shah R, Aldrovandi M, da Silva MC, Ingold I, et al. FSP1 is a Glutathione-Independent Ferroptosis Suppressor. *Nature* (2019) 575(7784):693–8. doi: 10.1038/s41586-019-1707-0

104. Brown CW, Amante JJ, Chhoy P, Elaimy AL, Liu H, Zhu LJ, et al. Prominin2 Drives Ferroptosis Resistance by Stabilizing Iron Export. *Dev Cell* (2019) 51(5):575–86.e6. doi: 10.1016/j.devcel.2019.10.007

105. Gout PW, Buckley AR, Simms CR, Bruchovsky N. Sulfasalazine, a Potent Suppressor of Lymphoma Growth by Inhibition of the X(C)- Cystine Transporter: A New Action for an Old Drug. *Leukemia* (2001) 15(10):1633–40. doi: 10.1038/sj.lj.97.402238

106. Tang B, Zhu J, Fang S, Wang Y, Vinuthkumar R, Li M, et al. Pharmacological Inhibition of MELK Restricts Ferroptosis and the Inflammatory Response in Colitis and Colitis-Propelled Carcinogenesis. *Free Radic Biol Med* (2021) 172:312–29. doi: 10.1016/j.freeradbiomed.2021.06.012

107. Iwamoto M, Koji T, Makiyama K, Kobayashi N, Nakane PK. A apoptosis of Crypt Epithelial Cells in Ulcerative Colitis. *J Pathol* (1996) 180(2):152–9. doi: 10.1002/(SICI)1096-9896(199610)180:2<152::AID-PATH649>3.0.CO;2-Y

108. Di Sabatino A, Ciccioppo R, Luinetti O, Ricciuti L, Moreira R, Cifone MG, et al. Increased Enterocyte Apoptosis in Inflamed Areas of Crohn’s Disease. *Dis Colon Rectum* (2003) 46(11):1498–507. doi: 10.1073/s10350-004-6802-z

109. Gunther C, Martini E, Wittkopf N, Amann K, Weigmann B, Neumann H, et al. Caspase-8 Regulates TNF-Alpha-Induced Epithelial Necroptosis and Terminal Ileitis. *Nature* (2011) 477(7364):335–9. doi: 10.1038/nature10400

110. Ma C, Yang D, Wang B, Wu C, Wu Y, Li S, et al. Gsdmerin in Macrophages Restrains Colitis by Controlling cGAS-Mediated Immune Response. *Sci Adv* (2020) 6(47):eabc4091. doi: 10.1126/sciadv.abc4091

111. Schwarzw R, Jiao H, Wachsmuth L, Tresch A, Pasparakis M. FADD and Caspase-8 Regulate Gut Homeostasis and Inflammation by Controlling MLKL- and GSDMD-Mediated Death of Intestinal Epithelial Cells. *Immunity* (2020) 52(6):978–93.e6. doi: 10.1016/j.immuni.2020.04.002

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.